Nadroparin

Generic Name: Nadroparin

Brand Names: Fraxiparine

Drug Type: Small Molecule

Unique Ingredient Identifier: 1K5KDI46KZ

Background: Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

Indication: Nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction.

Associated Conditions: Clotting, Deep Vein Thrombosis, Pulmonary Embolism, Unstable Angina Pectoris, Venous Thromboembolism, Non-q wave myocardial infarction, Thromboembolic phenomena

Clinical Trials

Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures

Phase 2

Conditions: Deep Vein Thrombosis
Pulmonary Embolism

Interventions: Drug: Fondaparinux
Drug: Nadroparin

First Posted Date: 2009-04-15

Last Posted Date: 2012-12-18

Lead Sponsor: Red Cross Hospital Beverwijk

Target Recruit Count: 669

Registration Number: NCT00881088

Locations: 🇳🇱
Medical Center Alkmaar, Alkmaar, North Holland, Netherlands
🇳🇱
University Medical Center Nijmegen, Nijmegen, Gelderland, Netherlands
🇳🇱
Red Cross Hospital, Beverwijk, N-Holland, Netherlands

and more 2 locations

A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery

Phase 3

Completed

Conditions: Thrombosis, Venous

Interventions: Drug: Fondaparinux sodium
Drug: Nadroparin

First Posted Date: 2009-02-13

Last Posted Date: 2016-03-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1351

Registration Number: NCT00843492

Locations: 🇪🇸
GSK Investigational Site, Vigo/Pontevedra, Spain

Nadroparin for the Initial Treatment of Pulmonary Thromboembolism

Phase 4

Completed

Conditions: Pulmonary Embolism
Thromboembolism
Vascular Diseases
Thrombosis

Interventions: Drug: Unfractionated heparin(UFH)
Drug: Nadroparin

First Posted Date: 2008-11-24

Last Posted Date: 2008-11-24

Lead Sponsor: Beijing Chao Yang Hospital

Target Recruit Count: 274

Registration Number: NCT00796692

Locations: 🇨🇳
The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳
The Affiliated Hospital of Medical College Jining, Jining, Shandong, China
🇨🇳
The Affiliated Hospital of Shenyang Medical University, Shenyang, Liaoning, China

and more 36 locations

Randomized Controlled Trial of Anticoagulation vs. Placebo for a First Symptomatic Isolated Distal Deep-vein Thrombosis (IDDVT)

Phase 3

Completed

Conditions: Distal (Calf) Deep-vein Thrombosis

Interventions: Drug: Placebo
Drug: nadroparine calcium

First Posted Date: 2007-01-12

Last Posted Date: 2018-05-04

Lead Sponsor: University Hospital, Geneva

Target Recruit Count: 260

Registration Number: NCT00421538

Locations: 🇨🇦
Royal University Hospital, Saskatoon, Saskatchewan, Canada
🇫🇷
Montpellier University Hospital, Montpellier, Languedoc, France
🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada

and more 4 locations